Eric Wong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Eric Wong has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Fred MacDonald
Centre for Lung Health - Covenant Health, 11111 Jasper Avenue, Edmonton, Alberta, Canada T5K 0L4
3 shared publications - Ambikaipakan Senthilselvan
School of Public Health, University of Alberta, Edmonton, AB T6G 1C9, Canada
2 shared publications - Carlos Frederico Lange
Department of Mechanical Engineering, University of Alberta, Edmonton, Canada
2 shared publications - Darcy D. Marciniuk
Respiratory Research Centre, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
2 shared publications - Dave Williams
Matsqui-Sumas-Abbotsford General Hospital, Abbotsford, Canada
2 shared publications - Don D. Sin
The University of British Columbia (Respiratory Division), Vancouver, BC
2 shared publications
Latest Publications
- 1 February 2014
- Published by Elsevier in Respiratory Physiology & Neurobiology
- Vol. 192, 30-38
Effect of modality on cardiopulmonary exercise testing in male and female COPD patients
- 1 February 2014
- Published by Elsevier in Respiratory Physiology & Neurobiology
- Vol. 192, 30-38
Effect of modality on cardiopulmonary exercise testing in male and female COPD patients
- Open Access
- 8 September 2013
- Published by Springer Nature in BMC Public Health
- Vol. 13 (1) , 811
Effectiveness of cough etiquette maneuvers in disrupting the chain of transmission of infectious respiratory diseases
The effectiveness of recommended measures, such as “cover your mouth when coughing”, in disrupting the chain of transmission of infectious respiratory diseases (IRD) has been questioned. The objective of the current study was to determine the effectiveness of simple primary respiratory hygiene/cough etiquette maneuvers in blocking droplets expelled as aerosol during coughing.
- 8 September 2013
- Published by Springer Nature in BMC Public Health
- Vol. 13 (1) , 811
Open AccessEffectiveness of cough etiquette maneuvers in disrupting the chain of transmission of infectious respiratory diseases
The effectiveness of recommended measures, such as “cover your mouth when coughing”, in disrupting the chain of transmission of infectious respiratory diseases (IRD) has been questioned. The objective of the current study was to determine the effectiveness of simple primary respiratory hygiene/cough etiquette maneuvers in blocking droplets expelled as aerosol during coughing.
- Open Access
- 21 March 2012
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 12 (1) , 11
Cough aerosol in healthy participants: fundamental knowledge to optimize droplet-spread infectious respiratory disease management
The Influenza A H1N1 virus can be transmitted via direct, indirect, and airborne route to non-infected subjects when an infected patient coughs, which expels a number of different sized droplets to the surrounding environment as an aerosol. The objective of the current study was to characterize the human cough aerosol pattern with the aim of developing a standard human cough bioaerosol model for Influenza Pandemic control.
- 21 March 2012
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 12 (1) , 11
Open AccessCough aerosol in healthy participants: fundamental knowledge to optimize droplet-spread infectious respiratory disease management
The Influenza A H1N1 virus can be transmitted via direct, indirect, and airborne route to non-infected subjects when an infected patient coughs, which expels a number of different sized droplets to the surrounding environment as an aerosol. The objective of the current study was to characterize the human cough aerosol pattern with the aim of developing a standard human cough bioaerosol model for Influenza Pandemic control.
- Open Access
- 6 February 2006
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 6 (1) , 1-8
Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? – study protocol for a randomized controlled trial [NCT00120978]
Background: Systemic inflammation is associated with various complications in chronic obstructive pulmonary disease including weight loss, cachexia, osteoporosis, cancer and cardiovascular diseases. Inhaled corticosteroids attenuate airway inflammation, reduce exacerbations, and improve mortality in chronic obstructive pulmonary disease. Whether inhaled corticosteroids by themselves or in combination with a long-acting β2-adrenoceptor agonist repress systemic inflammation in chronic obstructive pulmonary disease is unknown. The Advair Biomarkers in COPD (ABC) study will determine whether the effects of inhaled corticosteroids alone or in combination with a long-acting β2-adrenoceptor agonist reduce systemic inflammation and improve health status in patients with chronic obstructive pulmonary disease. Methods/Design: After a 4-week run-in phase during which patients with stable chronic obstructive pulmonary disease will receive inhaled fluticasone (500 micrograms twice daily), followed by a 4-week withdrawal phase during which all inhaled corticosteroids and long acting β2-adrenoceptor agonists will be discontinued, patients will be randomized to receive fluticasone (500 micrograms twice daily), fluticasone/salmeterol combination (500/50 micrograms twice daily), or placebo for four weeks. The study will recruit 250 patients across 11 centers in western Canada. Patients must be 40 years of age or older with at least 10 pack-year smoking history and have chronic obstructive pulmonary disease defined as forced expiratory volume in one second to vital capacity ratio of 0.70 or less and forced expiratory volume in one second that is 80% of predicted or less. Patients will be excluded if they have any known chronic systemic infections, inflammatory conditions, history of previous solid organ transplantation, myocardial infarction, or cerebrovascular accident within the past 3 months prior to study enrolment. The primary end-point is serum C-reactive protein level. Secondary end-points include circulating inflammatory cytokines such as interleukin-6 and interleukin-8 as well as health-related quality of life and lung function. Discussion: If inhaled corticosteroids by themselves or in combination with a long-acting β2-adrenoceptor agonist could repress systemic inflammation, they might greatly improve clinical prognosis by reducing various complications in chronic obstructive pulmonary disease.
- 6 February 2006
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 6 (1) , 1-8
Open AccessCan inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? – study protocol for a randomized controlled trial [NCT00120978]
Background: Systemic inflammation is associated with various complications in chronic obstructive pulmonary disease including weight loss, cachexia, osteoporosis, cancer and cardiovascular diseases. Inhaled corticosteroids attenuate airway inflammation, reduce exacerbations, and improve mortality in chronic obstructive pulmonary disease. Whether inhaled corticosteroids by themselves or in combination with a long-acting β2-adrenoceptor agonist repress systemic inflammation in chronic obstructive pulmonary disease is unknown. The Advair Biomarkers in COPD (ABC) study will determine whether the effects of inhaled corticosteroids alone or in combination with a long-acting β2-adrenoceptor agonist reduce systemic inflammation and improve health status in patients with chronic obstructive pulmonary disease. Methods/Design: After a 4-week run-in phase during which patients with stable chronic obstructive pulmonary disease will receive inhaled fluticasone (500 micrograms twice daily), followed by a 4-week withdrawal phase during which all inhaled corticosteroids and long acting β2-adrenoceptor agonists will be discontinued, patients will be randomized to receive fluticasone (500 micrograms twice daily), fluticasone/salmeterol combination (500/50 micrograms twice daily), or placebo for four weeks. The study will recruit 250 patients across 11 centers in western Canada. Patients must be 40 years of age or older with at least 10 pack-year smoking history and have chronic obstructive pulmonary disease defined as forced expiratory volume in one second to vital capacity ratio of 0.70 or less and forced expiratory volume in one second that is 80% of predicted or less. Patients will be excluded if they have any known chronic systemic infections, inflammatory conditions, history of previous solid organ transplantation, myocardial infarction, or cerebrovascular accident within the past 3 months prior to study enrolment. The primary end-point is serum C-reactive protein level. Secondary end-points include circulating inflammatory cytokines such as interleukin-6 and interleukin-8 as well as health-related quality of life and lung function. Discussion: If inhaled corticosteroids by themselves or in combination with a long-acting β2-adrenoceptor agonist could repress systemic inflammation, they might greatly improve clinical prognosis by reducing various complications in chronic obstructive pulmonary disease.
- Open Access
- 1 January 1999
- Published by Hindawi Limited in Canadian Respiratory Journal
- Vol. 6 (4) , 332-335
Cost Effectiveness of Transbronchial Needle Aspiration
OBJECTIVE: To evaluate the yield and cost effectiveness of transbronchial needle aspiration (TBNA) in the assessment of mediastinal and/or hilar lymphadenopathy.
- 1 January 1999
- Published by Hindawi Limited in Canadian Respiratory Journal
- Vol. 6 (4) , 332-335
Open AccessCost Effectiveness of Transbronchial Needle Aspiration
OBJECTIVE: To evaluate the yield and cost effectiveness of transbronchial needle aspiration (TBNA) in the assessment of mediastinal and/or hilar lymphadenopathy.